HIF1AN: A Potential Drug Target and Biomarker for Hypoxia Inducible Factor 1伪 (HIF1伪)

Target Name: HIF1AN

NCBI ID: G55662

HIF1AN

HIF1AN: A Potential Drug Target and Biomarker for Hypoxia Inducible Factor 1伪 (HIF1伪)

Hypoxia Inducible Factor 1伪 (HIF1伪) is a protein that plays a crucial role in responding to changes in oxygen levels in the body. When oxygen levels are low, HIF1伪 helps to coordinate the production of oxygen-carrying red blood cells, essential for delivering oxygen to tissues and organs. In addition to its role in oxygen transport, HIF1伪 is also involved in the regulation of angiogenesis, cell survival, and inflammation. As a result, HIF1伪 has been implicated in a wide range of diseases, including anemia, cancer, and neurodegenerative disorders.

One of the key challenges in studying HIF1伪 is its complex regulatory network. HIF1伪 is a protein that can be activated by various factors, including low oxygen levels, exercise, and radiation exposure. When HIF1伪 is activated, it can induce the production of erythropoietin (EPO), a protein that stimulates the production of red blood cells. HIF1伪 can also inhibit the degradation of its own protein, known as HIF1伪-尾, which may contribute to its persistence and stability.

While HIF1伪 has been studied extensively, the precise mechanisms that regulate its activity are not well understood. One potential mechanism involves the interaction between HIF1伪 and its downstream targets, including the transcription factor p53. p53 is a well-established regulator of gene expression that can induce or repress the activity of various transcription factors. In the context of HIF1伪, p53 has been shown to play a role in regulating the expression of genes involved in cell survival and angiogenesis.

Another potential mechanism that may involve HIF1伪 is its role in the regulation of cellular metabolism. HIF1伪 has been shown to be involved in the regulation of mitochondrial function and energy metabolism. In addition, HIF1伪 has been implicated in the regulation of cellular signaling pathways, including the TGF-β pathway. TGF-β is a well-established regulator of cell growth and differentiation that is involved in the development and maintenance of tissues and organs.

HIF1伪 has also been studied for its potential therapeutic applications. In an effort to treat anemia, researchers have investigated the potential use of HIF1伪 inhibitors as a new treatment for anemia. HIF1伪 inhibitors have been shown to be effective in increasing the production of red blood cells in individuals with anemia, potentially by enhancing the activity of HIF1伪. In addition, HIF1伪 inhibitors have also been shown to be effective in preventing the development of anemia in individuals with genetic disorders that are characterized by low red blood cell counts.

Another potential application of HIF1伪 inhibitors is their potential use as a cancer treatment. HIF1伪 has been shown to be involved in the regulation of angiogenesis, a process that is often associated with the development of cancer. As a result, HIF1伪 inhibitors have been investigated as a potential cancer therapeutic. In addition, HIF1伪 inhibitors have been shown to be effective in slowing the growth of cancer cells, potentially by inhibiting the activity of HIF1伪.

In addition to its potential therapeutic applications, HIF1伪 is also a potential biomarker for a wide range of diseases. HIF1伪 has been shown to be involved in the regulation of various cellular processes that are involved in disease development, including cancer, anemia, and neurodegenerative disorders. As a result, HIF1伪 has been proposed as a potential biomarker for a wide range of diseases.

In conclusion, HIF1伪 is a protein that plays a crucial role in responding to changes in oxygen levels in the body. While HIF1伪 has been studied extensively, many of its regulatory mechanisms and potential therapeutic applications remain to be fully understood. The potential drug target and biomarker properties of HIF1伪 make it an intriguing

Protein Name: Hypoxia Inducible Factor 1 Subunit Alpha Inhibitor

Functions: Hydroxylates HIF-1 alpha at 'Asn-803' in the C-terminal transactivation domain (CAD). Functions as an oxygen sensor and, under normoxic conditions, the hydroxylation prevents interaction of HIF-1 with transcriptional coactivators including Cbp/p300-interacting transactivator. Involved in transcriptional repression through interaction with HIF1A, VHL and histone deacetylases. Hydroxylates specific Asn residues within ankyrin repeat domains (ARD) of NFKB1, NFKBIA, NOTCH1, ASB4, PPP1R12A and several other ARD-containing proteins. Also hydroxylates Asp and His residues within ARDs of ANK1 and TNKS2, respectively. Negatively regulates NOTCH1 activity, accelerating myogenic differentiation. Positively regulates ASB4 activity, promoting vascular differentiation

The "HIF1AN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIF1AN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets